TABLE 1.
Evaluation of adverse reactions and CSF clinical signs after an immunization-and-challenge trial in pigs and of visible pathological lesions after postmortem examinationa
| Group | Pig | Postimmunization |
Postchallenge |
Postmortem |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LR | FD | FI | FD | FI | Dep | LPI | HS | KP | NI | NT | ||
| A (E2, 100 μg) | 4 | − | 0 | N | 0 | V | − | − | − | − | − | − |
| 7 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 10 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 18 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 19 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 22 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| B (E2, 50 μg) | 3 | − | 0 | N | 0 | N | − | − | − | − | − | − |
| 8 | − | 0 | N | 0 | V | − | − | − | + | − | − | |
| 20 | − | 0 | V | 0 | N | − | − | − | − | − | − | |
| 23 | − | 0 | N | 0 | N | − | + | − | − | − | − | |
| 28 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 29 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| C (E2, 25 μg) | 11 | − | 0 | N | 0 | N | − | − | − | + | − | − |
| 12 | − | 0 | N | 0 | V | − | − | − | − | − | − | |
| 15 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 24 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 26 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 30 | − | 0 | N | 0 | V | − | − | − | − | − | − | |
| D (purified E2, 25 μg) | 1 | − | 0 | N | 0 | N | − | − | − | − | − | − |
| 9 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 13 | − | 0 | N | 0 | N | − | − | − | + | − | − | |
| 21 | − | 0 | N | 0 | N | − | − | − | − | − | − | |
| 25 | − | 0 | N | 0 | V | − | − | − | − | − | − | |
| 27 | − | 0 | V | 0 | N | − | − | − | − | − | − | |
| E (placebo) | 2 | − | 0 | N | 8 | L | + | + | + | + | − | + |
| 5 | − | 0 | N | 10 | L | + | + | − | + | + | − | |
| 6 | − | 0 | N | 8 | L | + | + | + | + | + | + | |
| 14 | − | 0 | N | 10 | V | + | − | + | − | − | − | |
| 16 | − | 0 | V | 10 | L | + | + | + | + | + | + | |
| 17 | − | 0 | N | 8 | L | + | − | + | + | + | + | |
Pigs were immunized with different doses of E2-CSFV formulated within the whey of adenovirally transduced goats. Groups A to C received vaccine preparations containing 100, 50, and 25 μg of E2, respectively, in an oil-based adjuvant. Group D was immunized with 25 μg of E2 purified from the milk, while group E was injected with adjuvanted goat whey without E2 antigen. Two weeks after challenge, all animals were euthanized for necropsy and tissue analysis. Abbreviations: LR, local reactogenicity; FI, food intake (N, normal; V, variable; L, low); Dep, depression; PLL, perivascular lymphocyte infiltration in the brain; HS, hemorrhage in spleen; KP, kidney petechiae; NI, necrotic ileum; NT, necrotic tonsil; FD, number of days with fever (rectal temperature above 40°C).